Chronic Venous Occlusions Treatment Market By Treatment Type (Pharmacological Treatment, Interventional Procedures, Surgical Treatment), By Application (Chronic Venous Occlusions, Post-Thrombotic Syndrome, Varicose Veins), By End-User (Hospitals, Specialty Clinics, Ambulatory Care Centers, Home Care), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Chronic Venous Occlusions Treatment Market was valued at USD 3.2 billion in 2024-e and will surpass USD 5.9 billion by 2030; growing at a CAGR of 10.9% during 2025 - 2030.

The chronic venous occlusions treatment market is expanding as the global prevalence of venous diseases, particularly chronic venous occlusions (CVO), increases. CVO is a condition where veins in the lower extremities become blocked, resulting in symptoms such as pain, swelling, and ulcers. This condition is often linked to deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS), making it a major cause of disability. Treatment options for CVO aim to restore normal blood flow and reduce complications, including pharmacological treatments, interventional procedures, and surgical interventions. As the understanding of venous diseases advances, the market for innovative treatments is expected to grow further.

The market is also driven by technological advancements in medical devices and procedures, such as minimally invasive catheter-based interventions and advanced pharmacological therapies. The increasing demand for effective treatments, along with a growing aging population prone to venous disorders, is propelling the market. The availability of specialized treatment centers and better healthcare access for patients, particularly in developed regions, will continue to shape the market dynamics. As awareness around venous diseases increases, there is also a rising focus on preventative care and early intervention to reduce the risk of complications like varicose veins and post-thrombotic syndrome.

Interventional Procedures Are Fastest Growing Treatment Type Owing to Minimally Invasive Techniques

Interventional procedures are the fastest-growing treatment type in the chronic venous occlusions market, primarily due to the increasing preference for minimally invasive techniques. These procedures include endovenous laser treatment (EVLT), sclerotherapy, and catheter-directed thrombolysis. Interventional methods are gaining popularity because they offer a quicker recovery time, reduced risk of complications, and less pain compared to traditional surgical procedures. The ability to perform these procedures on an outpatient basis, with minimal disruption to the patient's lifestyle, has contributed to their growth.

The demand for interventional treatments is expected to continue rising as more patients seek effective solutions that provide faster results with fewer side effects. Technological innovations in catheter-based devices and imaging techniques have further improved the precision and efficacy of these procedures, making them an attractive option for patients and healthcare providers alike. As a result, interventional procedures will remain the fastest-growing treatment type in the chronic venous occlusions market.

Chronic Venous Occlusions Application is Largest Owing to High Incidence and Severity

The chronic venous occlusions application is the largest segment in the treatment market, owing to the high incidence and severity of the condition. Chronic venous occlusions, often caused by deep vein thrombosis (DVT), lead to long-term complications such as venous insufficiency, leg ulcers, and chronic pain. As the population ages, the prevalence of CVO is increasing, contributing to the demand for effective treatments. The management of CVO typically involves a combination of pharmacological and interventional approaches, aimed at restoring venous blood flow and alleviating symptoms.

In addition to the physical symptoms, CVO can also lead to significant reductions in quality of life, with patients often experiencing chronic pain and difficulty performing daily activities. The severity of the condition has made it a major focus for treatment innovation, driving the growth of this application segment. Given the serious nature of CVO and its long-term complications, this segment will continue to be the largest in the chronic venous occlusions treatment market.

Hospitals End-User is Largest Due to Comprehensive Treatment Offerings

Hospitals are the largest end-user segment in the chronic venous occlusions treatment market, as they provide comprehensive treatment offerings that address both acute and chronic venous conditions. Hospitals are equipped with advanced diagnostic tools and specialized care teams, including vascular surgeons and interventional radiologists, making them the preferred setting for managing chronic venous occlusions. Hospitals are also capable of providing a wide range of treatments, including pharmacological therapies, interventional procedures, and surgical options.

Moreover, hospitals have the resources to manage complex cases of CVO, including those with associated complications like post-thrombotic syndrome or varicose veins. They also play a critical role in post-operative care, providing monitoring and rehabilitation services to ensure optimal recovery for patients. As healthcare systems around the world continue to expand their capabilities in treating venous disorders, hospitals will remain the largest end-user segment in the chronic venous occlusions treatment market.

North America Region is Largest Due to Advanced Healthcare Infrastructure and High Treatment Demand

North America is the largest region in the chronic venous occlusions treatment market, driven by advanced healthcare infrastructure, high treatment demand, and widespread access to specialized care. The United States, in particular, has a well-developed healthcare system, with a high level of access to medical professionals skilled in treating chronic venous conditions. Additionally, the prevalence of risk factors such as obesity and a sedentary lifestyle contributes to a higher incidence of venous diseases in North America, further driving the demand for treatment options.

The region is also home to many leading healthcare providers and medical device companies that are developing innovative treatments for CVO. As healthcare professionals and patients become more aware of the available treatment options, North America will continue to be the largest region for chronic venous occlusions treatments. The adoption of new technologies, such as minimally invasive procedures, is also contributing to the growth of the market in this region.

Leading Companies and Competitive Landscape

The chronic venous occlusions treatment market is competitive, with several key players leading the charge in developing innovative treatment options. Prominent companies in the market include Medtronic, Boston Scientific, and Edwards Lifesciences, which offer a range of medical devices and interventional products designed to treat venous disorders. These companies are investing in research and development to create more effective, minimally invasive treatments for CVO, as well as expanding their portfolios to include drugs and devices that cater to the broader venous disease treatment market.

Additionally, smaller biotech and medical device companies are also contributing to the competitive landscape, particularly in the development of novel therapies for venous insufficiency and post-thrombotic syndrome. The market is expected to remain highly competitive, with ongoing advancements in technology and treatment methods. Collaboration between healthcare providers, medical device manufacturers, and pharmaceutical companies will be essential for addressing the growing demand for effective and affordable treatments for chronic venous occlusions.

Recent Developments:

• In December 2024, Boston Scientific Corporation launched a new endovenous laser system aimed at improving patient outcomes in chronic venous occlusions treatment.
• In November 2024, Medtronic PLC received approval for a new thrombectomy device designed for chronic venous occlusions, enhancing the effectiveness of venous clot removal.
• In October 2024, Abbott Laboratories expanded its portfolio with a next-generation venous stent, providing better long-term outcomes for patients with chronic venous occlusions.
• In September 2024, Biotronik SE & Co. KG introduced a new balloon angioplasty catheter designed to improve precision and safety during venous procedures.
• In August 2024, Teleflex Incorporated launched an advanced sclerotherapy agent to provide more effective vein sealing for patients with chronic venous disease.

List of Leading Companies:

• Boston Scientific Corporation
• Medtronic PLC
• Abbott Laboratories
• Biotronik SE & Co. KG
• Endo International PLC
• Teleflex Incorporated
• AngioDynamics, Inc.
• Stryker Corporation
• Siemens Healthineers
• Cook Medical, Inc.
• Vascular Solutions, Inc.
• Terumo Corporation
• Gore Medical
• Cordis Corporation
• Becton, Dickinson and Company

Report Scope: